// App-Quantinova.ai

133 : Feasibility of multimodal molecular characterization of the androgen receptor (AR) in circulating tumor cells (CTCs) from patients with castrate-resistant prostate cancer (CRPC).

Researchers

Presenter

  • David James Vander

Principal Investigators

  • Masis Isikbay

  • Edwin Reyes

  • Ryan Duggan

  • Alicia J. Wyche

  • Walter Michael Stadler

  • Donald Vander Griend

  • Russell Zelig Szmulewitz

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

  • Epithelial Cell Adhesion Molecule

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved